Alder BioPharmaceuticals, Inc. announced that it will present additional analyses of the efficacy and quality of life data from clinical trials of eptinezumab, Alder’s lead investigational product candidate for migraine prevention, at the 71st Annual American Academy of Neurology (AAN) Meeting in Philadelphia being held May 4-10, 2019. On April 22, 2019, Alder announced that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s Biologics License Application (BLA) for eptinezumab. Eptinezumab data will be the subject of multiple platform and poster presentations, including a platform presentation on the data related to early onset of migraine prevention and consistency across four eptinezumab clinical trials. In-depth analyses will also be presented on patients’ global impression of change related to improvement in most bothersome migraine symptoms following treatment with eptinezumab. Additional presentations provide further assessments of eptinezumab’s efficacy and effects on quality of life.